0001209191-18-005827.txt : 20180129 0001209191-18-005827.hdr.sgml : 20180129 20180129161457 ACCESSION NUMBER: 0001209191-18-005827 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180125 FILED AS OF DATE: 20180129 DATE AS OF CHANGE: 20180129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cha Albert CENTRAL INDEX KEY: 0001397906 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 18555670 MAIL ADDRESS: STREET 1: 505 HAMILTON AVENUE, SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER NAME: FORMER CONFORMED NAME: CHA ALBERT DATE OF NAME CHANGE: 20070427 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Menlo Therapeutics, Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4085 CAMPBELL AVENUE, SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-486-1416 MAIL ADDRESS: STREET 1: 4085 CAMPBELL AVENUE, SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-25 0 0001566044 Menlo Therapeutics, Inc. MNLO 0001397906 Cha Albert 204 CARDINAL WAY, 2ND FLOOR REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2018-01-25 4 P 0 258432 17.00 A 258432 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-25 4 P 0 35686 17.00 A 35686 I By Vivo Capital Surplus Fund III, L.P. Common Stock 2018-01-29 4 C 0 2348550 A 2606982 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-29 4 C 0 324306 A 359992 I By Vivo Capital Surplus Fund III, L.P. Common Stock 2018-01-29 4 C 0 917559 A 3524541 I By Vivo Capital Fund VIII, L.P. Common Stock 2018-01-29 4 C 0 126703 A 486695 I By Vivo Capital Surplus Fund III, L.P. Series B Preferred Stock 2018-01-29 4 C 0 6335215 0.00 D Common Stock 2348550 0 I By Vivo Capital Fund VIII, L.P. Series B Preferred Stock 2018-01-29 4 C 0 874817 0.00 D Common Stock 324306 0 I By Vivo Capital Surplus Fund III, L.P. Series C Preferred Stock 2018-01-29 4 C 0 2475118 0.00 D Common Stock 917559 0 I By Vivo Capital Fund VIII, L.P. Series C Preferred Stock 2018-01-29 4 C 0 341784 0.00 D Common Stock 126703 0 I By Vivo Capital Surplus Fund III, L.P. The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. /s/ Stephen Thau as attorney-in-fact 2018-01-29